Daily Endocrinology Research Analysis
Three papers stand out today: a mechanistic study reveals that SENP2-mediated deSUMOylation of ERRα is crucial for UCP1-driven thermogenesis in brown adipocytes; a multi-country pediatric study introduces FH-PeDS and an AI model that improve detection of familial hypercholesterolemia; and a large-scale cohort analysis suggests that adding liothyronine (T3) to levothyroxine therapy in hypothyroidism may lower risks of dementia and mortality.
Summary
Three papers stand out today: a mechanistic study reveals that SENP2-mediated deSUMOylation of ERRα is crucial for UCP1-driven thermogenesis in brown adipocytes; a multi-country pediatric study introduces FH-PeDS and an AI model that improve detection of familial hypercholesterolemia; and a large-scale cohort analysis suggests that adding liothyronine (T3) to levothyroxine therapy in hypothyroidism may lower risks of dementia and mortality.
Research Themes
- Post-translational regulation of adipose thermogenesis
- AI-enhanced pediatric cardiovascular risk diagnostics
- Thyroid hormone replacement strategies and long-term outcomes
Selected Articles
1. SENP2 regulates UCP1-dependent thermogenesis in brown adipocytes via deSUMOylation of ERRα.
Using a Ucp1-Cre SENP2 knockout, the authors show that SENP2 is required for β3-adrenergic/cold-induced thermogenesis and metabolic flexibility in brown adipose tissue. Mechanistically, SENP2 deSUMOylates ERRα, enabling ERRα/PGC1α-driven activation of the Ucp1 promoter; SUMOylated ERRα exhibits impaired DNA binding and reduced assembly of the transcriptional complex.
Impact: Identifies a previously unrecognized post-translational regulatory axis (SENP2–ERRα deSUMOylation) that controls UCP1 expression and brown fat thermogenesis, linking SUMOylation to systemic metabolic health.
Clinical Implications: While preclinical, targeting the SENP2–ERRα deSUMOylation pathway could offer a strategy to enhance thermogenesis for obesity and insulin resistance; biomarkers of SUMOylation status in adipose tissue may inform future metabolic therapies.
Key Findings
- Brown adipocyte-specific SENP2 knockout aggravated high-fat diet–induced insulin resistance and impaired cold/β3-adrenergic-induced thermogenesis.
- SENP2 deSUMOylates ERRα, enhancing ERRα/PGC1α-mediated activation of the Ucp1 promoter and transcriptional complex assembly.
- SUMOylation of ERRα disrupts ERRE DNA binding at the Ucp1 promoter, blunting UCP1 induction.
Methodological Strengths
- Genetic, cell-type–specific knockout in vivo with physiologic (cold, β3-agonist) challenges.
- Mechanistic dissection of transcriptional regulation (ERRα deSUMOylation, promoter activity, complex assembly).
Limitations
- Preclinical mouse model without human validation.
- Potential off-target effects or developmental compensation with Ucp1-Cre were not fully excluded.
Future Directions: Validate SENP2–ERRα deSUMOylation in human BAT, assess druggability of SENP2 or ERRα SUMOylation modulators, and test metabolic outcomes in diet-induced obesity models with pharmacologic intervention.
Brown adipose tissue (BAT) is responsible for energy homeostasis and adaptive thermogenesis. SUMO-specific protease 2 (SENP2) plays an essential role in adipogenesis; however, the role of SENP2 in BAT metabolism has not been explored. Here we investigated the role of SENP2 in mature brown adipocytes with a brown adipocyte-specific SENP2 knockout (Senp2-BKO) mouse model generated using the uncoupling protein 1 (Ucp1)-Cre. High-fat diet-induced insulin resistance was aggravated in Senp2-BKO mice compared with control mice. In Senp2-
2. Proposal of a Familial Hypercholesterolemia Pediatric Diagnostic Score (FH-PeDS).
Across Slovenian (N=1,360) and Portuguese (N=340) pediatric hypercholesterolemia cohorts, FH-PeDS and an AI model (ML-FH-PeDS) outperformed established criteria (e.g., DLCN). FH-PeDS achieved AUC 0.897 vs. 0.857 for DLCN, while ML-FH-PeDS reached AUC 0.932 (training), 0.904 (testing), and 0.867 on external validation, enabling better prioritization for genetic testing.
Impact: Provides practical, validated tools—both rule-based and AI—to improve early identification of pediatric FH where genetic testing is limited, addressing a critical gap in preventive cardiometabolic care.
Clinical Implications: Clinicians can use FH-PeDS/ML-FH-PeDS to triage hypercholesterolemic children for genetic testing and early lipid-lowering therapy, potentially reducing lifelong ASCVD risk through earlier intervention.
Key Findings
- Only 47.4% of genetically confirmed FH cases were identified by all five established pediatric criteria; 10.9% were missed entirely.
- FH-PeDS outperformed DLCN in combined cohorts (AUC 0.897 vs. 0.857; p<0.01).
- ML-FH-PeDS achieved AUC 0.932 (training), 0.904 (testing), and 0.867 on external validation, with 87.7% PPV at 98% specificity as a confirmatory tool.
Methodological Strengths
- Multi-cohort development with external validation across distinct populations.
- Direct benchmarking against five established diagnostic criteria with genetic variants as reference standard.
Limitations
- Cross-sectional design without outcome-based clinical validation.
- Performance may vary with local prevalence, lipid measurement methods, and ancestry; prospective implementation studies are needed.
Future Directions: Prospective, multi-ethnic implementation trials integrating FH-PeDS/ML-FH-PeDS into EHRs, assessing cost-effectiveness, clinical outcomes, and cascade screening yield.
BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) significantly increases cardiovascular risk from childhood yet remains widely underdiagnosed. This cross-sectional study aimed to evaluate existing pediatric FH diagnostic criteria in real-world cohorts and to develop two novel diagnostic tools: a semi-quantitative scoring system (FH-PeDS) and a machine learning model (ML-FH-PeDS) to enhance early FH detection. METHODS: Five established FH diagnostic criteria were assesed (Dutch Lipid Cl
3. Treatment of Hypothyroidism that Contains Liothyronine is Associated with Reduced Risk of Dementia and Mortality.
In a matched retrospective cohort of 1.26M hypothyroid patients versus 3.32M controls, hypothyroidism was associated with ~1.4× dementia risk and >2× mortality, even with normal TSH. Compared with LT4 monotherapy, T3-containing therapy was associated with 16–31% lower risks of dementia and mortality; a parallel meta-analysis also showed ~1.4× higher dementia risk with hypothyroidism.
Impact: Challenges the long-standing LT4-only paradigm by linking T3-containing therapy to lower dementia and mortality risks, generating hypotheses that warrant randomized trials.
Clinical Implications: Consider selective T3 combination therapy in hypothyroid patients with persistent symptoms or high neurocognitive risk despite normal TSH, while awaiting RCTs; emphasize individualized dosing and monitoring for cardiovascular safety.
Key Findings
- Hypothyroidism was associated with ~1.4-fold higher dementia risk and >2-fold higher mortality versus controls, even with normal TSH.
- Compared with LT4 monotherapy, T3-containing regimens were associated with 16–31% reductions in dementia and mortality risks after propensity matching and Cox adjustment.
- A parallel meta-analysis of 12 studies found ~1.4× higher dementia risk in hypothyroidism, supporting the cohort findings.
Methodological Strengths
- Very large real-world dataset with propensity score matching and adjusted Cox models; long follow-up (up to 20 years).
- Parallel systematic review/meta-analysis corroborated dementia association with hypothyroidism.
Limitations
- Observational design with potential residual confounding and treatment selection bias; T3 dosing/adherence and indication nuances may not be fully captured.
- Outcomes like atrial fibrillation and subgroup heterogeneity are not fully detailed in the abstract.
Future Directions: Conduct randomized controlled trials comparing LT4 vs. LT4+T3 with cognitive, survival, and cardiovascular safety endpoints; refine patient selection using biomarkers and digital phenotyping.
INTRODUCTION: Standard levothyroxine (LT4) therapy may not fully address all risks associated with hypothyroidism-especially cognitive decline, dementia, and mortality-even when TSH levels are normalized. Observational studies link hypothyroidism to higher dementia rates; the role of LT4 plus liothyronine (T3) therapies remains uncertain. METHODS: This retrospective cohort study analyzed TriNetX data, comparing 1.26 million patients with hypothyroidism (on LT4, LT4+T3, or desiccated thyroid extrac